Candel Therapeutics Target of Unusually Large Options Trading (NASDAQ:CADL)

Candel Therapeutics, Inc. (NASDAQ:CADL) saw some unusual options trading on Thursday. Stock traders acquired 3,231 call options on the stock. This represents an increase of 329% compared to the typical daily volume of 753 call options.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Candel Therapeutics in a report on Monday, November 18th.

Insider Activity at Candel Therapeutics

In other news, insider William Garrett Nichols sold 13,935 shares of Candel Therapeutics stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $4.56, for a total transaction of $63,543.60. Following the completion of the transaction, the insider now directly owns 100,547 shares in the company, valued at approximately $458,494.32. This trade represents a 12.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the sale, the insider now owns 929,873 shares in the company, valued at $5,597,835.46. The trade was a 1.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,127 shares of company stock worth $349,911 over the last ninety days. 41.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new position in shares of Candel Therapeutics during the 2nd quarter valued at $162,000. Rhumbline Advisers bought a new stake in shares of Candel Therapeutics during the 2nd quarter valued at about $143,000. Point72 DIFC Ltd purchased a new stake in shares of Candel Therapeutics during the 2nd quarter valued at about $31,000. Bank of New York Mellon Corp purchased a new stake in shares of Candel Therapeutics during the 2nd quarter valued at about $338,000. Finally, MetLife Investment Management LLC purchased a new position in shares of Candel Therapeutics in the third quarter worth approximately $87,000. 13.93% of the stock is owned by hedge funds and other institutional investors.

Candel Therapeutics Trading Up 26.5 %

Candel Therapeutics stock opened at $9.80 on Friday. Candel Therapeutics has a one year low of $1.02 and a one year high of $14.60. The business’s fifty day moving average is $5.31 and its 200 day moving average is $6.09. The stock has a market capitalization of $318.26 million, a PE ratio of -5.66 and a beta of -0.95. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.18 and a quick ratio of 1.18.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.